Landvoigt Maple T, Mullett Charles J
Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV, USA.
Pediatr Crit Care Med. 2006 May;7(3):245-8. doi: 10.1097/01.PCC.0000216683.00110.0E.
To examine the efficacy of octreotide in resolving chylothoraces in infants and children following cardiac surgery.
Retrospective chart review.
Pediatric intensive care unit of a tertiary care center.
All children who received octreotide for the treatment of chylothoraces following surgery for congenital heart disease over a 30-month period between 2001-2004.
Octreotide infusion.
Eight courses of octreotide treatment were identified in seven patients who met our inclusion criteria. The median duration of therapy was 5 days, and dosing ranged from 1 to 4 microg/kg/hr. Treatment did not result in an overall decrease in average chest tube output after 3 days of therapy. However, in two patients (29%) the chylothoraces ultimately resolved during the octreotide infusion. Treatment was well tolerated, and no serious side effects were noted.
In contrast to previously published reports, we find octreotide therapy for postoperative chylothoraces to be successful in only a minority of cases.
探讨奥曲肽对婴幼儿及儿童心脏手术后乳糜胸的治疗效果。
回顾性病历审查。
一家三级护理中心的儿科重症监护病房。
2001年至2004年期间，所有在先天性心脏病手术后接受奥曲肽治疗乳糜胸的儿童。
奥曲肽输注。
在符合纳入标准的7例患者中确定了8个疗程的奥曲肽治疗。治疗的中位持续时间为5天，给药剂量范围为1至4微克/千克/小时。治疗3天后，平均胸管引流量并未整体减少。然而，2例患者（29%）在奥曲肽输注期间乳糜胸最终得以消退。治疗耐受性良好，未观察到严重副作用。
与先前发表的报告不同，我们发现奥曲肽治疗术后乳糜胸仅在少数病例中取得成功。
